Kendra N. Avery
Beckman Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kendra N. Avery.
Nature Communications | 2015
Can Kucuk; Bei Jiang; Xiaozhou Hu; Zhang Wy; John K. C. Chan; Wenming Xiao; Nathan A. Lack; Can Alkan; John C. Williams; Kendra N. Avery; Painar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Liu Wp; Kai Fu; Laurence de Leval; Timothy W. McKeithan; Wing C. Chan
Lymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), γδ-T-cell lymphomas (n=43) and their cell lines (n=9) through next generation and/or Sanger sequencing. STAT5B N642H is particularly frequent in all forms of γδ-T-cell lymphomas. STAT3 and STAT5B mutations are associated with increased phosphorylated protein and a growth advantage to transduced cell lines or normal NK cells. Growth-promoting activity of the mutants can be partially inhibited by a JAK1/2 inhibitor. Molecular modelling and surface plasmon resonance measurements of the N642H mutant indicate a marked increase in binding affinity of the phosphotyrosine-Y699 with the mutant histidine. This is associated with the prolonged persistence of the mutant phosphoSTAT5B and marked increase of binding to target sites. Our findings suggest that JAK-STAT pathway inhibition may represent a therapeutic strategy.
Scientific Reports | 2015
Kendra N. Avery; Cindy Zer; Krzysztof Bzymek; John C. Williams
Functionalization of monoclonal antibodies (mAbs) requires chemical derivatization and/or genetic manipulation. Inherent in these methods are challenges with protein heterogeneity, stability and solubility. Such perturbations could potentially be avoided by using a high affinity, non-covalent intermediate to bridge the desired functionality to a stable mAb. Recently, we engineered a binding site for a peptide named “meditope” within the Fab of trastuzumab. Proximity of the meditope site to that of protein L suggested an opportunity to enhance the meditopes moderate affinity. Joined by a peptide linker, the meditope-protein L construct has a KD ~ 180 pM - a 7000-fold increase in affinity. The construct is highly specific to the engineered trastuzumab, as demonstrated by flow cytometry. Moreover, the fusion of a bulky GFP to this construct did not affect the association with cell surface antigens. Collectively, these data indicate this specific, high affinity construct can be developed to rapidly add new functionality to mAbs.
Nature Communications | 2018
Krzysztof P. Bzymek; James W. Puckett; Cindy Zer; Jun Xie; Yuelong Ma; Jeremy D. King; Leah H. Goodstein; Kendra N. Avery; David Colcher; Gagandeep Singh; David Horne; John C. Williams
Because monoclonal antibodies (mAbs) have exceptional specificity and favorable pharmacology, substantial efforts have been made to functionalize them, either with potent cytotoxins, biologics, radionuclides, or fluorescent groups for therapeutic benefit and/or use as theranostic agents. To exploit our recently discovered meditope–Fab interaction as an alternative means to efficiently functionalize mAbs, we used insights from the structure to enhance the affinity and lifetime of the interaction by four orders of magnitude. To further extend the lifetime of the complex, we created a mechanical bond by incorporating an azide on the meditope, threading the azide through the Fab, and using click chemistry to add a steric group. The mechanically interlocked, meditope–Fab complex retains antigen specificity and is capable of imaging tumors in mice. These studies indicate it is possible to “snap” functionality onto mAbs, opening the possibility of rapidly creating unique combinations of mAbs with an array of cytotoxins, biologics, and imaging agents.Meditope-Fab is a peptide-antibody complex potentially useful for drug delivery and diagnostic, but a short half-life prevents its use in vivo. Here the authors engineer the complex to improve its stability, create functionalized antibodies by click chemistry and use them for in vivo tumor imaging.
Journal of the American Chemical Society | 2018
Ottavia Golfetto; Devin L. Wakefield; Eliedonna E. Cacao; Kendra N. Avery; Victor Kenyon; Raphael Jorand; Steven J. Tobin; Sunetra Biswas; Jennifer Gutierrez; Ronald Clinton; Yuelong Ma; David Horne; John C. Williams; Tijana Jovanovic-Talisman
Quantitative single molecule localization microscopy (qSMLM) is a powerful approach to study in situ protein organization. However, uncertainty regarding the photophysical properties of fluorescent reporters can bias the interpretation of detected localizations and subsequent quantification. Furthermore, strategies to efficiently detect endogenous proteins are often constrained by label heterogeneity and reporter size. Here, a new surface assay for molecular isolation (SAMI) was developed for qSMLM and used to characterize photophysical properties of fluorescent proteins and dyes. SAMI-qSMLM afforded robust quantification. To efficiently detect endogenous proteins, we used fluorescent ligands that bind to a specific site on engineered antibody fragments. Both the density and nano-organization of membrane-bound epidermal growth factor receptors (EGFR, HER2, and HER3) were determined by a combination of SAMI, antibody engineering, and pair-correlation analysis. In breast cancer cell lines, we detected distinct differences in receptor density and nano-organization upon treatment with therapeutic agents. This new platform can improve molecular quantification and can be developed to study the local protein environment of intact cells.
Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2017
Krzysztof P. Bzymek; Yuelong Ma; Kendra N. Avery; David Horne; John C. Williams
The structure–affinity relationship of complexes of the cetuximab Fab with meditope peptides modified at Arg8 is investigated.
Archive | 2012
John C. Williams; Cindy Zer; Kendra N. Avery
Archive | 2011
John C. Williams; Joshua Michael Donaldson; David Horne; Yuelong Ma; Cindy Zer; Krzysztof Bzymek; Kendra N. Avery
Protein Engineering Design & Selection | 2017
Cindy Zer; Kendra N. Avery; Kassondra Meyer; Leah H. Goodstein; Krzysztof P. Bzymek; Gagandeep Singh; John C. Williams
Biophysical Journal | 2015
Ottavia Golfetto; Eliedonna E. Cacao; Raphael Jorand; Sunetra Biswas; Cindy Zer; Kendra N. Avery; John C. Williams; Tijana Jovanovic-Talisman
Archive | 2012
John C. Williams; David Horne; Yuelong Ma; Heng Wei Chang; Joshua Michael Donaldson; Cindy Zer; Krzysztof Bzymek; Kendra N. Avery; Jun Xie